How does ARA-290 (Cibinetide) work?
Erythropoietin-derived peptide that activates the innate-repair receptor (heteromer of EPO-R and CD131) without triggering erythropoiesis. Reduces inflammation and supports nerve and tissue healing without raising red blood cells. In plain terms, ARA-290 (Cibinetide) is a compound studied for calming nerve pain and inflammation without raising red blood cells. An EPO-derived peptide that targets the innate-repair receptor without the red-blood-cell side of erythropoietin, studied for neuropathic pain, sarcoidosis, and diabetic complications. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Users with neuropathic pain (small-fiber neuropathy)
- Sarcoidosis patients (Phase 2 data)
- Healing stacks for nerve-involved injuries
References
- ARA-290 (cibinetide) in sarcoidosis-associated small fiber neuropathy — Heij L et al., Mol Med, 2012
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — Dahan A, Dunne A, Swartjes M, et al. (Brines M, senior author) — Molecular Medicine, 2013
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Brines M, Dunne AN, van Velzen M, et al. — Molecular Medicine, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ARA-290 (Cibinetide)
Last updated 2026-06-06.